Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, has entered into a clinical trial collaboration and supply agreement with Merck & Co., under which a Phase 2 clinical study will evaluate PRT3789, Prelude’s investigational, highly selective, first-in-class SMARCA2 degrader in combination with KEYTRUDA (pembrolizumab) Merck’s anti-PD-1 therapy, in patients with SMARCA4-mutated cancers. “We are excited for this opportunity to work together with Merck on this s...